Peloton shares sink on earnings miss, soft revenue outlook

Impact · against what's priced in

Peloton is facing a valuation reset as weak holiday hardware demand and a shrinking subscription base undermine its growth narrative, despite improving cost controls. Genflow Biosciences sees a positive catalyst from strengthened IP protections for its therapeutic pipeline.

PTON−0.60

No priced-in read yet

In context

A holiday quarter revenue miss ($657M vs $674M estimate) and a 7% YoY drop in paid subscriptions to 2.66 million indicate fundamental demand weakness that outweighs raised EBITDA guidance.

Read from the article alone

• guidance▲4%
• earnings
• GENF
• PTON
• ai hardware
• connected fitness
• consumer discretionary
• ebitda
• holiday sales